Xspray - Buying Opportunity (Sponsored Research, TP SEK175, 8 pgs)
Yesterday’s news that Xspray’s generic HyNap-Dasa showed bioequivalence to Sprycel in fed patients but failed to show bioequivalence in fasting patients is not much of a surprise to us given the large variability in Sprycel’s bioavailability. Xspray’s technology allows it to create amorphous forms of existing PKI’s but with higher bioavailability and crucially, it allows Xspray to circumvent existing formulation patents. Xspray’s improved version of Sprycel will be filed in the US in Q421 and has a real opportunity to offer a meaningful solution for patients who require PPI’s. Yesterday’s share price fall is a buying opportunity, in our view.For access to the full note and our initiation, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.